Involvement of kallikrein in the antihypertensive response to furosemide in essential hypertension

A. R. Olshan, D. T. O'Connor, Richard A Preston, R. P. Frigon, R. A. Stone

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Twelve white men with essential hypertension were treated for 1 month in randomized order with either placebo or low-dose furosemide (40 mg/day) and compared to 22 race-, age-, and diet-matched normal controls. Furosemide therapy significantly reduced mean arterial pressure (108.6 ± 2.4 vs. 101.0 ± 2.7 mm Hg, p<0.02) in association with a significant increase in 24 hr urinary kallikrein activity (7.9 ± 1.8 vs. 13.4 ± 2.8 esterase units/24 hr, p<0.02). Normal controls on no therapy excreted 19.4 ± 2.6 esterase units/24 hr of urinary kallikrein activity, significantly greater than hypertensives on placebo (p<0.01) but not hypertensives on furosemide (p>0.1). The decrease in mean arterial pressure and the increase in urinary kallikrein activity induced by furosemide were not associated with a demonstrable change in renal hemodynamics, plasma renin activity, or plasma aldosterone concentration, but they were associated with a significant increase in intravascular volume (5,876 ± 339 vs. 6,808 ± 346 ml, p<0.01). A significant (p<0.05) inverse correlation between mean arterial pressure and urinary kallikrein activity suggests a possible role for the kallikrein-kinin system in the antihypertensive mechanism of furosemide.

Original languageEnglish
Pages (from-to)161-167
Number of pages7
JournalJournal of Cardiovascular Pharmacology
Volume3
Issue number1
StatePublished - Feb 9 1981
Externally publishedYes

Fingerprint

Kallikreins
Furosemide
Antihypertensive Agents
Tissue Kallikreins
Arterial Pressure
Kallikrein-Kinin System
Aldosterone
Renin
Hemodynamics
Placebos
Diet
Kidney
Essential Hypertension
Therapeutics

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine

Cite this

Involvement of kallikrein in the antihypertensive response to furosemide in essential hypertension. / Olshan, A. R.; O'Connor, D. T.; Preston, Richard A; Frigon, R. P.; Stone, R. A.

In: Journal of Cardiovascular Pharmacology, Vol. 3, No. 1, 09.02.1981, p. 161-167.

Research output: Contribution to journalArticle

Olshan, A. R. ; O'Connor, D. T. ; Preston, Richard A ; Frigon, R. P. ; Stone, R. A. / Involvement of kallikrein in the antihypertensive response to furosemide in essential hypertension. In: Journal of Cardiovascular Pharmacology. 1981 ; Vol. 3, No. 1. pp. 161-167.
@article{de752a28c0da4c338f42df0628208c68,
title = "Involvement of kallikrein in the antihypertensive response to furosemide in essential hypertension",
abstract = "Twelve white men with essential hypertension were treated for 1 month in randomized order with either placebo or low-dose furosemide (40 mg/day) and compared to 22 race-, age-, and diet-matched normal controls. Furosemide therapy significantly reduced mean arterial pressure (108.6 ± 2.4 vs. 101.0 ± 2.7 mm Hg, p<0.02) in association with a significant increase in 24 hr urinary kallikrein activity (7.9 ± 1.8 vs. 13.4 ± 2.8 esterase units/24 hr, p<0.02). Normal controls on no therapy excreted 19.4 ± 2.6 esterase units/24 hr of urinary kallikrein activity, significantly greater than hypertensives on placebo (p<0.01) but not hypertensives on furosemide (p>0.1). The decrease in mean arterial pressure and the increase in urinary kallikrein activity induced by furosemide were not associated with a demonstrable change in renal hemodynamics, plasma renin activity, or plasma aldosterone concentration, but they were associated with a significant increase in intravascular volume (5,876 ± 339 vs. 6,808 ± 346 ml, p<0.01). A significant (p<0.05) inverse correlation between mean arterial pressure and urinary kallikrein activity suggests a possible role for the kallikrein-kinin system in the antihypertensive mechanism of furosemide.",
author = "Olshan, {A. R.} and O'Connor, {D. T.} and Preston, {Richard A} and Frigon, {R. P.} and Stone, {R. A.}",
year = "1981",
month = "2",
day = "9",
language = "English",
volume = "3",
pages = "161--167",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Involvement of kallikrein in the antihypertensive response to furosemide in essential hypertension

AU - Olshan, A. R.

AU - O'Connor, D. T.

AU - Preston, Richard A

AU - Frigon, R. P.

AU - Stone, R. A.

PY - 1981/2/9

Y1 - 1981/2/9

N2 - Twelve white men with essential hypertension were treated for 1 month in randomized order with either placebo or low-dose furosemide (40 mg/day) and compared to 22 race-, age-, and diet-matched normal controls. Furosemide therapy significantly reduced mean arterial pressure (108.6 ± 2.4 vs. 101.0 ± 2.7 mm Hg, p<0.02) in association with a significant increase in 24 hr urinary kallikrein activity (7.9 ± 1.8 vs. 13.4 ± 2.8 esterase units/24 hr, p<0.02). Normal controls on no therapy excreted 19.4 ± 2.6 esterase units/24 hr of urinary kallikrein activity, significantly greater than hypertensives on placebo (p<0.01) but not hypertensives on furosemide (p>0.1). The decrease in mean arterial pressure and the increase in urinary kallikrein activity induced by furosemide were not associated with a demonstrable change in renal hemodynamics, plasma renin activity, or plasma aldosterone concentration, but they were associated with a significant increase in intravascular volume (5,876 ± 339 vs. 6,808 ± 346 ml, p<0.01). A significant (p<0.05) inverse correlation between mean arterial pressure and urinary kallikrein activity suggests a possible role for the kallikrein-kinin system in the antihypertensive mechanism of furosemide.

AB - Twelve white men with essential hypertension were treated for 1 month in randomized order with either placebo or low-dose furosemide (40 mg/day) and compared to 22 race-, age-, and diet-matched normal controls. Furosemide therapy significantly reduced mean arterial pressure (108.6 ± 2.4 vs. 101.0 ± 2.7 mm Hg, p<0.02) in association with a significant increase in 24 hr urinary kallikrein activity (7.9 ± 1.8 vs. 13.4 ± 2.8 esterase units/24 hr, p<0.02). Normal controls on no therapy excreted 19.4 ± 2.6 esterase units/24 hr of urinary kallikrein activity, significantly greater than hypertensives on placebo (p<0.01) but not hypertensives on furosemide (p>0.1). The decrease in mean arterial pressure and the increase in urinary kallikrein activity induced by furosemide were not associated with a demonstrable change in renal hemodynamics, plasma renin activity, or plasma aldosterone concentration, but they were associated with a significant increase in intravascular volume (5,876 ± 339 vs. 6,808 ± 346 ml, p<0.01). A significant (p<0.05) inverse correlation between mean arterial pressure and urinary kallikrein activity suggests a possible role for the kallikrein-kinin system in the antihypertensive mechanism of furosemide.

UR - http://www.scopus.com/inward/record.url?scp=0019380012&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019380012&partnerID=8YFLogxK

M3 - Article

C2 - 6160345

AN - SCOPUS:0019380012

VL - 3

SP - 161

EP - 167

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

IS - 1

ER -